TG Therapeutics (TGTX) Misses Q3 EPS by 19c

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of ($0.50), $0.19 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $38.1 thousand versus the consensus estimate of $30 thousand.

Cash, cash equivalents, investment securities, and interest receivable were $60.7 million as of September 30, 2016.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy